## **Horizon scanning - COC 2022**

## In this guide

## In this guide

- 1. About the Committees 2022
- 2. COT Preface 2022
- 3. COT evaluations 2022
- 4. Committee Procedures 2022
- 5. Ongoing Work COT 2022
- 6. Other Committee Activities Joint Expert Groups and Presentations -2022
- 7. 2022 Membership of the Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment
- 8. <u>Committee on Mutagenicity of chemicals in Food, Consumer Products and the Environment Annual Report 2022</u>
- 9. Ongoing work COM 2022
- 10. COM Evaluations 2022
- 11. Horizon scanning: meetings and workshops COM 2022
- 12. OECD guidelines COM 2022
- 13. 2022 Membership of the Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment
- 14. <u>Committee on Carcinogenicity of Chemicals in Food, Consumer Products and</u> the Environment Annual Report 2022
- 15. COC Ongoing Topics 2022
- 16. COC Joint ongoing topics 2022
- 17. COC Workshop 2022
- 18. Joint session COC 2022
- 19. Horizon scanning COC 2022
- 20. Working Groups COC 2022
- 21. Guidance statements COC 2022
- 22. <u>2022 Membership of the Committee on Carcinogenicity of Chemicals in Food,</u> <u>Consumer Products and the Environment</u>
- 23. Annex 1 2022 Terms of Reference
- 24. Annex 2 2022 Code of Conduct for members of the COC/COM/COT
- 25. Annex 3 2022 Openness

- 26. Annex 4 2022 Good Practice Agreement for Scientific Advisory Committees
- 27. Annex 5 2022 Glossary of Terms
- 3.16 The COC undertakes horizon scanning exercises at regular intervals with the aim of identifying new and emerging issues which have potential to impact on public health.
- 3.17 In 2022, the Committee continued to have a standing agenda item for each meeting on horizon scanning topics and to update the COC on upcoming topics for UK and international scientific advisory groups. A full horizon scanning discussion was held in November 2021 and the COC will review the priority topics from the subsequent horizon scanning discussions in 2023.
- 3.18 At the end of discussion in 2021, it was agreed that the priority topics were:
  - Maintain a watching brief on factors affecting cancer susceptibility including shift work, stress and other lifestyle factors and how that might affect assessment of chemicals and carcinogenicity.
  - Consider an update to guidance on assessment of nanomaterials, possibly as a joint activity across COC, COM and COT.
  - Gain awareness of the potential effects of antibiotics and antivirals on the microbiome.
  - Consider a joint discussion with COM on thresholds for in vivo mutagens and whether there is new information subsequent to the 2010 COM opinion.
  - Endocrine disruption and the link with carcinogenicity, acknowledging that endocrine disruption is also within the COT remit.
  - Impact of chemicals on potential for metastasis or progression of cancer, in particular with respect to the tumour microenvironment.
  - Communication of cancer risk and how COC should be involved with this, especially with the move away from a yes/no decision on whether a substance is a carcinogen, and ensuring consistency in describing risks, possibly starting with a landscape review of terminology across a number of Committees (FSA and UKHSA) and led by Lay Members.
  - Ensuring appropriate considerations are made to acknowledging diversity in the population especially where there might be differences in risk between different groups.